GSK’s financials: CEO Walmsley touts results, expectations via video
GSK’s latest quarterly financials released early Wednesday in London include an upgrade in expectations. Watch CEO Emma Walmsley’s video summary.
Read More
GSK
GSK strikes $1 billion licensing, development deal for potential hepatitis B treatment
GSK will pay some $1 billion to acquire rights to and commercialize an hepatitis B therapy from Johnson & Johnson in a deal announced Tuesday.
Read More
GSK signs $20M deal to license genetic data from 23andMe
Drug giant GSK has struck a $20 million one-year deal to gain access to genetics information from 23andMe. The news comes just ahead of GSK’s latest financial report which is due Wednesday.
Read More
GSK, ViiV Healthcare to chronicle infectious disease fighting efforts at conference
GSK and ViiV Healthcare will share new data on its industry-leading infectious diseases pipeline and portfolio at the Infectious Disease Society of America’s IDWeek 2023 annual meeting.
Read More
GSK lands $3B shingles vaccine distribution deal in China
Drug giant GSK will expand its sales reach for its Shingrix shingles vaccine in China under terms of a $3 billion deal announced Monday.
Read More
GSK sues Pfizer in battle over respiratory virus vaccine patents
Drug giants GSK and Pfizer, both with a significant presence in North Carolina, are in a legal battle now over respiratory virus vaccines that received FDA approval in May.
Read More
GSK’s ‘strong results’ could mean boost for CEO Walmsley: Reuters
GSK CEO Emma Walmsley delivered an upbeat video overview of the drug giant’s latest financial report on Wednesday. And in a statement she further amplified her remarks. But adding to her smile: what the financial report and a positive look ahead could mean for her.
Read More
GSK sells shares in company it spun off, reportedly raising $1B
GSK is selling shares worth some $1 billion it had held onto when it spun off Haleon in 2022. Here’s what’s happening.
Read More
RSV vaccine from GSK is first to win approval from FDA
The U.S. approved the first vaccine for RSV on Wednesday, shots to protect older adults against a respiratory virus that’s most notorious for attacking babies but endangers their grandparents, too.
Read More
